Next Article in Journal
Are Patients with Active Cancer and Those with History of Cancer Carrying the Same Risks of Recurrent VTE and Bleeding While on Anticoagulants?
Next Article in Special Issue
Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
Previous Article in Journal
Emerging Therapeutic Activity of Davallia formosana on Prostate Cancer Cells through Coordinated Blockade of Lipogenesis and Androgen Receptor Expression
Previous Article in Special Issue
Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes
Review

The Landscape of Targeted Therapies in TNBC

Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(4), 916; https://doi.org/10.3390/cancers12040916
Received: 23 February 2020 / Revised: 24 March 2020 / Accepted: 27 March 2020 / Published: 8 April 2020
Triple negative breast cancer (TNBC) constitutes the most aggressive molecular subtype among breast tumors. Despite progress on the underlying tumor biology, clinical outcomes for TNBC unfortunately remain poor. The median overall survival for patients with metastatic TNBC is approximately eighteen months. Chemotherapy is the mainstay of treatment while there is a growing body of evidence that targeted therapies may be on the horizon with poly-ADP-ribose polymerase (PARP) and immune check-point inhibitors already established in the treatment paradigm of TNBC. A large number of novel therapeutic agents are being evaluated for their efficacy in TNBC. As novel therapeutics are now incorporated into clinical practice, it is clear that tumor heterogeneity and clonal evolution can result to de novo or acquired treatment resistance. As precision medicine and next generation sequencing is part of cancer diagnostics, tailored treatment approaches based on the expression of molecular markers are currently being implemented in clinical practice and clinical trial design. The scope of this review is to highlight the most relevant current knowledge regarding underlying molecular profile of TNBC and its potential application in clinical practice. View Full-Text
Keywords: triple negative breast cancer; molecular profiling; DNA damage repair; targeted treatment; personalized medicine triple negative breast cancer; molecular profiling; DNA damage repair; targeted treatment; personalized medicine
Show Figures

Figure 1

MDPI and ACS Style

Vagia, E.; Mahalingam, D.; Cristofanilli, M. The Landscape of Targeted Therapies in TNBC. Cancers 2020, 12, 916. https://doi.org/10.3390/cancers12040916

AMA Style

Vagia E, Mahalingam D, Cristofanilli M. The Landscape of Targeted Therapies in TNBC. Cancers. 2020; 12(4):916. https://doi.org/10.3390/cancers12040916

Chicago/Turabian Style

Vagia, Elena, Devalingam Mahalingam, and Massimo Cristofanilli. 2020. "The Landscape of Targeted Therapies in TNBC" Cancers 12, no. 4: 916. https://doi.org/10.3390/cancers12040916

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop